Search results: Found 3

Listing 1 - 3 of 3
Sort by
Basal ganglia: physiological, behavioral, and computational studies

Authors: --- --- ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889193882 Year: Pages: 494 DOI: 10.3389/978-2-88919-388-2 Language: English
Publisher: Frontiers Media SA
Subject: Science (General)
Added to DOAB on : 2015-12-03 13:02:24
License:

Loading...
Export citation

Choose an application

Abstract

The basal ganglia has received much attention over the last two decades, as it has been implicated in many neurological and psychiatric disorders. Most of this research - in both animals and humans - attempt to understand the neural and biochemical substrates of basic motor and learning processes, and how these are affected in human patients as well as animal models of brain disorders. The current volume contains research articles and reviews describing basic, pre-clinical and clinical neuroscience research of the basal ganglia written by attendees of the 11th Triennial Meeting of the International Basal Ganglia Society (IBAGS) that was held March 3-7th, 2013 at the Princess Hotel, Eilat, Israel and by researchers of the basal ganglia. Specifically, articles in this volume include research reports on the biochemistry, computational theory, anatomy and physiology of single neurons and functional circuitry of the basal ganglia networks as well as the latest data on animal models of basal ganglia dysfunction and clinical studies in human patients.

Preclinical and clinical issues in Alzheimer's disease drug research and development

Authors: ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889194339 Year: Pages: 100 DOI: 10.3389/978-2-88919-433-9 Language: English
Publisher: Frontiers Media SA
Subject: Therapeutics --- Science (General)
Added to DOAB on : 2016-01-19 14:05:46
License:

Loading...
Export citation

Choose an application

Abstract

Alzheimer’s disease (AD) is a chronic neurodegenerative disorder characterized by progressive cognitive dysfunction and memory loss, inability to perform the activities of daily living and mood disorders. According to the so-called “amyloid cascade hypothesis”, amyloid-ß- peptide (Aß), produced by beta- and gamma- secretase-mediated cleavages of the amyloid precursor protein (APP), plays a pivotal role in the pathogenesis of AD. Aß was also shown to contribute to AD pathology by stimulating the hyperphosphorylation of tau which is responsible for the formation of neurofibrillary tangles. However, the “amyloid cascade hypothesis” was challenged by other theories which lend support to the idea that Aß is not causative but can be considered as an “innocent bystander” in AD. Although preclinical research generated impressive lines of evidence about the several intracellular mechanism(s) whose impairment leads to the onset and progression of AD, clinical research aimed at the development of new drugs capable of preventing or delaying the onset of neuronal damage in AD patients has produced limited results. The drugs currently available for the treatment of AD are acetylcholinesterase inhibitors (AChEI) and the NMDA glutamate receptor antagonist memantine. The AChEI increase acetylcholine levels in the synaptic cleft, which are reduced because of the progressive damage of cholinergic neurons in cognitive brain areas (e.g. amygdala, hippocampus, and frontal cortex), whereas memantine is used to prevent/reduce calcium-dependent excitotoxic neuronal cell death. Both classes of drugs have been shown to improve symptoms related to cognitive decline, but their effects are confined largely to patients with mild to moderate AD, in particular during the first year or so of treatment. An alternative to this symptomatic treatments involves the use of drugs that intervene in the pathogenesis of the disease. Recently, monoclonal antibodies against Aß were proposed as novel agents capable to remove Aß from the brain thus preventing neuronal damage. The research topic focuses on the preclinical and clinical evidence about the several factors that contribute to the pathogenesis of AD as well as the potential therapeutic role of new classes of drugs still under preclinical or clinical development.

Models and Estimation of Genetic Effects

Authors: ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889194445 Year: Pages: 99 DOI: 10.3389/978-2-88919-444-5 Language: English
Publisher: Frontiers Media SA
Subject: Ecology --- Genetics --- Science (General)
Added to DOAB on : 2016-02-05 17:24:33
License:

Loading...
Export citation

Choose an application

Abstract

Ronald Fisher needed to develop elaborate models of genetic effects in order to set the foundations of Quantitative Genetics in his 1918 paper “The correlation between relatives on the supposition of Mendelian inheritance”. Since then, many significant implementations have been made to model genetic effects. However, at the verge of one century after Fisher’s kick-off, models of genetic effects keep on being discussed and implemented. Indeed, the relatively recent advent of QTL analyses challenged the state of the art of this field by providing researchers the opportunity to obtain and analyze estimates of genetic effects from real data. In this context, the development of this field was not exempt of some polemics, like the debate about the convenience of the functional and the statistical epistasis approaches. This research topic is meant to provide recent developments in models and estimation of genetic effects and to enrich the discussion about how and why models of genetic effects must be further developed and applied.The articles in this Research Topic shall thus extend, refine and/or provide a refresh look at Fisher’s original models of genetic effects and their application to genetic effects estimation and to improve our understanding of evolutionary processes and breeding programs.

Listing 1 - 3 of 3
Sort by
Narrow your search

Publisher

Frontiers Media SA (3)


License

CC by (3)


Language

english (3)


Year
From To Submit

2015 (3)